tirzepatide eyes Clinical studies have found that patients with type 2 diabetes who had no prior eye disorders, and were prescribed Zepbound (tirzepatide) had an increased risk of developing NAION (Non-Arteritic Use of the dual GIP/GLP-1

GLP-1 medications carry a documented but rare risk of acute pancreatitis

Penn Holderness, a family influencer, has the highest genetic risk for Alzheimer's

PlexusDx explains the biology behind weight rebound and how sustained semaglutide treatment maintains long-term results

Explore tirzepatides pharmacodynamics, clinical evidence, and metabolic benefits

Headline results from OASIS 1 - a phase 3a 68-week, efficacy and safety trial comparing once-daily oral semaglutide 50 mg for weight management to placebo in 667 adults with obesity or overweight with one or more comorbidities have revealed the trial achieved its primary endpoint by demonstrating a statistically significant and superior weight loss at week 68 with oral semaglutide 50mg versus placebo.When evaluating the effects of treatment if all people adhered to treatment from a mean baseli

Adults with type 2 diabetes receiving tirzepatide had significantly greater declines in urine albumin-to-creatinine ratio than those receiving comparators such as placebo or another therapy, researchers reported